Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Pollock

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
Cardiovascular Diabetology|November 29, 2023
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trialAkihiko Koshino, Brendon L Neuen, Niels Jongs, et al.
Kidney International Reports|April 18, 2023
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective CohortJuan Jose Garcia Sanchez, Glen James, Juan Jesus Carrero, et al.
Advances in Therapy|April 18, 2023
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical TrialBartholomeus J A Willigers, Mario Ouwens, Andrew Briggs, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
Diabetes, Obesity & Metabolism|January 9, 2025
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trialAmanda Siriwardana, Luke Buizen, Min Jun, et al.
BMJ Open|March 7, 2024
Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complicationsMustafa Arici, Samir Helmy Assaad-Khalil, Marcello Casaccia Bertoluci, et al.
Kidney International Reports|February 22, 2021
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin ReceptorMegumi Oshima, Akinori Hara, Tadashi Toyama, et al.
Kidney International Reports|May 20, 2024
Framework of Guidelines for Management of CKD in AsiaCarol Pollock, Ju-Young Moon, Le Pham Ngoc Ha, et al.
Contributions to Nephrology|June 1, 2011
Outcomes of patients with planned initiation of hemodialysis in the IDEAL trialJohn Collins, Bruce Cooper, Pauline Branley, et al.
Kidney International|February 17, 2012
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insightsIain C Macdougall, Simon D Roger, Angel de Francisco, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Cardiovascular Diabetology|November 29, 2023
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trialAkihiko Koshino, Brendon L Neuen, Niels Jongs, et al.
Kidney International Reports|April 18, 2023
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective CohortJuan Jose Garcia Sanchez, Glen James, Juan Jesus Carrero, et al.
Advances in Therapy|April 18, 2023
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical TrialBartholomeus J A Willigers, Mario Ouwens, Andrew Briggs, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
Diabetes, Obesity & Metabolism|January 9, 2025
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trialAmanda Siriwardana, Luke Buizen, Min Jun, et al.
BMJ Open|March 7, 2024
Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complicationsMustafa Arici, Samir Helmy Assaad-Khalil, Marcello Casaccia Bertoluci, et al.
Kidney International Reports|February 22, 2021
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin ReceptorMegumi Oshima, Akinori Hara, Tadashi Toyama, et al.
Kidney International Reports|May 20, 2024
Framework of Guidelines for Management of CKD in AsiaCarol Pollock, Ju-Young Moon, Le Pham Ngoc Ha, et al.
Contributions to Nephrology|June 1, 2011
Outcomes of patients with planned initiation of hemodialysis in the IDEAL trialJohn Collins, Bruce Cooper, Pauline Branley, et al.
Kidney International|February 17, 2012
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insightsIain C Macdougall, Simon D Roger, Angel de Francisco, et al.
Pageof 17